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Abstract.
Background: The temporal relationship of cognitive deficit and functional impairment in Alzheimer’s disease (AD) is not well
characterized. Recent analyses suggest cognitive decline predicts subsequent functional decline throughout AD progression.
Objective: To better understand the relationship between cognitive and functional decline in mild AD using autoregressive
cross-lagged (ARCL) panel analyses in several clinical trials.
Methods: Data included placebo patients with mild AD pooled from two multicenter, double-blind, Phase 3 solanezumab
(EXPEDITION/2) or semagacestat (IDENTITY/2) studies, and from AD patients participating in the Alzheimer’s Disease
Neuroimaging Initiative (ADNI). Cognitive and functional outcomes were assessed using AD Assessment Scale-Cognitive
subscale (ADAS-Cog), AD Cooperative Study-Activities of Daily Living instrumental subscale (ADCS-iADL), or Functional
Activities Questionnaire (FAQ), respectively. ARCL panel analyses evaluated relationships between cognitive and functional
impairment over time.
Results: In EXPEDITION, ARCL panel analyses demonstrated cognitive scores significantly predicted future functional impair-
ment at 5 of 6 time points, while functional scores predicted subsequent cognitive scores in only 1 of 6 time points. Data from
IDENTITY and ADNI programs yielded consistent results whereby cognition predicted subsequent function, but not vice-versa.
Conclusions: Analyses from three databases indicated cognitive decline precedes and predicts subsequent functional decline in
mild AD dementia, consistent with previously proposed hypotheses, and corroborate recent publications using similar method-
ologies. Cognitive impairment may be used as a predictor of future functional impairment in mild AD dementia and can be
considered a critical target for prevention strategies to limit future functional decline in the dementia process.
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INTRODUCTION
Clinical trials of potential treatments for Alz-
heimer’s disease (AD) currently require co-primary
endpoints of cognition and function or global clinical
status to be assessed independently to satisfy regula-
tory requirements. Longitudinal studies of persons at
risk for AD have demonstrated the initial clinical pre-
sentation of AD is one in which there are cognitive
deficits measurable with performance-based tests, but
with no evident loss of activities of daily living. This
initial state is frequently referred to as mild cognitive
impairment (MCI) or prodromal AD [1, 2]. The earliest
functional deficits, as patients advance to mild demen-
tia, are often difficult to characterize [3]. To enable
more informative studies in MCI and mild AD demen-
tia, a better understanding of the relationship between
cognitive and functional progression in milder stages
of dementia due to AD is needed.
Recent evidence has suggested that AD is a
continuum, with the clinical symptoms of overt
dementia becoming apparent a decade or more after
the biomarker-associated pathophysiological process
begins in sporadic AD [4–9] and autosomal dom-
inant AD [10]. Biomarker studies investigating the
early stages of neurodegeneration have postulated
that, following pathophysiological changes, cogni-
tive impairment occurs first followed by functional
impairment [11]. Based on this biomarker evidence
of AD pathology, recent academic workgroups have
established new diagnostic criteria to span the AD
continuum [1, 4, 12, 13].
The early stages of AD, from preclinical to MCI,
are defined clinically by the level of cognitive impair-
ment alone [1], as functional deficits are not apparent
until later in the disease process. Consequently, demon-
strating the benefits of disease-modifying treatments
on function in patients in early stages of the disease is
inherently difficult. There have been limited publica-
tions showing functional effects in mild AD patients.
Few studies involving symptomatic drugs approved
for mild to severe AD dementia patients temporarily
showed improved cognition and stabilization of func-
tion with limited or no improvement above baseline in
mild AD. One study by Potkin and colleagues (2002)
supported the hypothesis that functional impairment
differs across the AD continuum, and that treatment
with rivastigmine, a cholinesterase inhibitor, produced
modest improvement in function across all disease
stages; however, the effects were dependent on level of
impairment and frequency of functional activity [14].
In mild-moderate AD dementia populations, currently
approved symptomatic treatments including rivastig-
mine, galantamine, memantine, and donepezil improve
cognition and generally may preserve function only
over longer periods [15–19].
Auto-regressive cross-lagged (ARCL) panel anal-
ysis is a classical structural equation model used to
simultaneously analyze multiple outcomes that are
measured repeatedly over time. It is designed to assess
the strength of potential reciprocal causal relationships
between the outcomes and explore inference of influ-
ence of one variable over another [20, 21]. Previous
studies have used this model to investigate the tem-
poral order and causal relationship between nicotine
dependence and average smoking [22] and cognitive-
behavioral interventions and chronic pain [23].
While few empirical data have been reported,
a recent publication by Zahodne and colleagues
(2013) explored the relationship between cognition
and function using ARCL panel analysis in two lon-
gitudinal studies with non-demented and demented
older adults [24]. The two studies included were
the population-based Washington Heights/Hamilton
Heights Inwood Columbia Aging Project (WHICAP)
with non-demented older adults and the clinical trial
Predictors Study with patients with probable AD
dementia, which measured cognitive and functional
abilities for 18 to 24 months and over 6 years, respec-
tively. In these studies, cognitive impairment more
consistently predicted subsequent functional impair-
ment in non-demented older adults, a subset who
eventually developed dementia, and in patients with
prevalent AD. The authors stated these data support
the theory that functional impairment may be a direct
result of cognitive impairment [24].
The objective of this post-hoc analysis was to better
understand the temporal relationship between cogni-
tive and functional decline in mild AD dementia. Our
previous publication found that cognitive impairment
is more evident than functional impairment in mild
AD dementia [25]. These results are consistent with
the hypothesis that cognitive decline is the core symp-
tom of AD and that functional impairment is primarily
caused by and follows cognitive decline in the natural
course of the disease progression. This post-hoc anal-
ysis explores this hypothesis more directly by utilizing
ARCL analyses to investigate the potential reciprocal
causal-effect between cognitive impairment and func-
tional impairment and compares the relative strength
of the two directions.
We hypothesize that the ARCL panel analyses will
demonstrate that cognitive decline precedes and pre-
dicts functional decline during the natural disease
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Table 1
Patient Demographics in mild AD Dementia
Category EXPEDITION Placebo (n= 663) IDENTITY Placebo (n= 629) ADNI (n= 336)
Age, mean (SD), years 73.3 (7.9) 73.6 (7.9) 75.1 (7.8)
Female % 54.6 53.7 44.4
Race, white % 84.2 74.7 92.7
APOE4 carriers % 59.8 57.1 67.2
Education, mean (SD), years 12.6 (3.9) 12.5 (3.8) 15.2 (3.0)
MMSE (baseline), mean (SD) 22.5 (2.8) 22.7 (2.7) 23.2 (2.1)
EXPEDITION and IDENTITY include mild AD dementia patients treated with placebo. ADNI includes mild AD dementia patients with no
investigational treatment. ADNI, Alzheimer’s Disease Neuroimaging Initiative; MMSE, Mini Mental State Examination; SD, standard deviation.
progression of mild AD dementia, while the reciprocal
direction is not supported.
METHODS
EXPEDITION program
EXPEDITION and EXPEDITION2 were two mul-
ticenter, double-blind, Phase 3 studies of solanezumab.
Pooled placebo patients with mild AD dementia
(Mini-Mental State Examination [MMSE] score 20
to 26, n= 663), were included in this post-hoc anal-
ysis. Solanezumab, a humanized monoclonal antibody
designed to clear soluble amyloid- (A) from the
brain, was studied as a potential disease-modifying
agent for the treatment of AD, and the primary
outcomes of the trials (EXPEDITION and EXPE-
DITION2) have been reported previously [26]. All
patients provided informed consent before participa-
tion in the EXPEDITION study program, and the study
protocols were approved by ethical review boards.
Patient demographics are shown in Table 1.
Cognitive and functional outcome measures were
assessed at baseline and at 6 post-baseline time points
every 3 months for 18 months in the EXPEDI-
TION studies. Cognitive ability was assessed using
the 14-item AD Assessment Scale-Cognitive sub-
scale (ADAS-Cog14) with a score range of 0 to 90
(with higher scores indicating greater disability) [27].
Function was measured with the AD Cooperative
Study-Activities of Daily Living Scale instrumental
subscale (ADCS-iADL), comprised of items 7 through
23 of the ADCS-ADL scale, with scores from 0 to 56
(lower score denoting greater functional loss).
IDENTITY program
A similar clinical trial dataset of pooled placebo-
treated, mild AD dementia patients (MMSE score 20
to 26) from two multicenter, double-blind, Phase 3
semagacestat studies (IDENTITY and IDENTITY2,
n= 629) was also included in the analyses. Semagace-
stat, a -secretase inhibitor, was studied as another
putative disease-modifying agent for the treatment of
AD. Treatment in both studies was terminated prema-
turely based on data that showed cognitive worsening
in patients treated with semagacestat compared to
placebo. Patients were then followed up for seven
months to collect additional safety data. The results
from the IDENTITY studies have been reported pre-
viously [28]. All patients provided informed consent
before participation in the IDENTITY study program,
and the study protocols were approved by ethical
review boards. Additional patient demographics are
included in Table 1.
Cognitive and functional outcome measures were
the same as those of the EXPEDITION study program
and were collected at baseline and at 6 post-baseline
time points every 3 months for 18 months.
ADNI
A third dataset included mild AD patients from
the AD Neuroimaging Initiative (ADNI) database
(MMSE score 20 to 26, n= 336) [29]. Additional
patient demographics are included in Table 1. ADNI
is a natural history, longitudinal, non-treatment study
that was launched in 2003 by the National Institute
on Aging (NIA), the National Institute of Biomedical
Imaging and Bioengineering (NIBIB), the Food and
Drug Administration (FDA), private pharmaceutical
companies, and non-profit organizations as a $60-
million, 5-year public/private partnership. ADNI is
structured like a clinical trial but does not pro-
vide an intervention. For up-to-date information, see
http://www.adni-info.org.
Cognitive and functional outcome measures in
ADNI included time points at baseline and after 6, 12,
and 24 months. In the ADNI dataset, cognition was
evaluated with the 11-item ADAS-Cognitive subscale
(ADAS-Cog11) with score range of 0 to 70 [27, 30] and
function was measured with the Functional Activities
Questionnaire (FAQ) [31] with scores ranging from 0
to 30 (higher score representing more impairment).
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Statistical analyses
Mean scores with standard deviations for each visit
on both cognitive and functional measures are shown
in Table 2. Spearman rank correlations between the
absolute values of cognitive and functional outcome
measures at baseline and for each post-baseline visit
were determined for each dataset.
ARCL panel analyses were used to evaluate the
structural relationships between cognitive and func-
tional impairment based on the longitudinal data over
the course of the studies. In the ARCL model, the
interrelationship between cognitive performance and
functional abilities are evaluated based on the esti-
mates of the autoregressive coefficients from time (t-1)
to time (t), , as well as the cross-lagged regression
coefficients from time (t-1) to time (t), . The cor-
relation between the two outcome variables, ρ, was
also estimated [22] (Fig. 1). Full Information Maxi-
mum Likelihood estimation was used to make use of
all available data from all patients.
The overall model fit was determined using three
standard measures, including the comparative fit index
(CFI), root mean square error of approximation
(RMSEA), and standardized root mean square resid-
ual (SRMR) [21]. A model was considered acceptable
with values of RMSEA <0.08, SRMR <0.05, and
CFI >0.95 [24]. All analyses were performed using
SAS9.2.
Table 2
Cognitive and functional scores at each time point in mild AD
dementia
Months Cognitiona Functionb
Mean (SD) Mean (SD)
EXPEDITION Placebo Baseline 29.6 (8.8) 43.9 (9.5)
3 29.8 (9.6) 42.0 (10.2)
6 30.9 (10.8) 41.3 (10.7)
9 30.9 (11.5) 40.5 (10.8)
12 33.4 (12.1) 39.6 (11.4)
15 34.0 (13.1) 38.4 (11.9)
18 35.8 (14.4) 37.1 (12.8)
IDENTITY Placebo Baseline 30.2 (8.6) 41.6 (10.9)
3 30.0 (9.2) 41.1 (10.6)
6 30.9 (10.3) 40.1 (11.4)
9 30.8 (11.0) 39.7 (11.2)
12 33.2 (11.9) 39.0 (11.9)
15 34.1 (12.8) 37.8 (12.3)
18 34.0 (14.1) 37.7 (12.3)
ADNI Baseline 19.7 (6.8) 13.2 (7.0)
6 21.5 (7.9) 15.5 (7.4)
12 22.8 (8.8) 17.3 (7.2)
24 27.9 (11.9) 20.3 (7.1)
EXPEDITION and IDENTITY include mild AD dementia patients
treated with placebo. ADNI includes mild AD dementia patients
with no investigational treatment. aCognitive measures included:
ADAS-Cog14 for EXPEDITION and IDENTITY study programs;
ADAS-Cog11 for ADNI. bFunctional measures included: ADCS-
iADL for EXPEDITION and IDENTITY study programs; FAQ
for ADNI. ADAS-Cog, AD Assessment Scale-Cognitive subscales;
ADCS-iADL, AD Cooperative Study-Activities of Daily Living
instrumental subscale; ADNI, Alzheimer’s Disease Neuroimaging
Initiative; FAQ, Functional Activities Questionnaire; SD, standard
deviation.
Fig. 1. Path diagram of the autoregressive cross-lagged panel analysis model to assess the interrelationship between cognitive and functional
longitudinal data. Autoregressive and cross-lagged coefficients (, ) were estimated from time (t-1) to time (t) for cognition and function, and
the correlations between the two outcome variables (ρ) was also estimated (modified from Zahodne et al. [24]).
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Fig. 2. Correlations between cognitive and functional measures in EXPEDITION, IDENTITY, and ADNI study programs. EXPEDITION and
IDENTITY include mild AD dementia patients treated with placebo. ADNI includes mild AD dementia patients with no investigational treatment.
All correlations include absolute values for comparisons across the different scales. EXPEDITION and IDENTITY compared ADAS-Cog14
versus ADCS-iADL and ADNI compared ADAS-Cog11 versus FAQ.
RESULTS
EXPEDITION program
In the EXPEDITION study program, the Spearman
rank correlation between ADAS-Cog14 and ADCS-
iADL was 0.333 at baseline and increased to 0.630
after 18 months (Fig. 2). The ARCL panel analysis
model fit statistics for the EXPEDITION study pro-
gram were, RMSEA = 0.04 with a 90% confidence
interval of (0.03, 0.05), SRMR = 0.06, and CFI = 0.99
(Table 3). Results demonstrated cognitive impairment
significantly predicts future functional impairment in
5 of 6 time points (all time points except 6 month
predicting 9 month). Functional scores predicted cog-
nitive outcome in only 1 of 6 time points (6 month
predicting 9 month) when the same analyses were
performed to test the reverse hypothesis. The mag-
nitude of cross-lagged coefficients was, in general,
greater for cognition predicting subsequent function
than for function predicting cognition (Table 4). The
direction of the cross-lagged regression coefficient
indicates that a more impaired cognitive score pre-
dicts a more impaired functional score at subsequent
visits.
Table 3
Model fit statistics for ARCL panel analyses in mild AD dementia
RMSEA RMSEA 90% CI SRMR CFI
EXPEDITION 0.04 (0.03, 0.05) 0.06 0.99
Placebo
IDENTITY 0.07 (0.06, 0.09) 0.05 0.98
Placebo
ADNI 0.08 (0.03, 0.12) 0.02 0.99
EXPEDITION and IDENTITY include mild AD dementia patients
treated with placebo. ADNI includes mild AD dementia patients
with no investigational treatment. All regression coefficients are
standardized. ADNI, Alzheimer’s Disease Neuroimaging Initiative;
ARCL, autoregressive cross-lagged; CFI, comparative fit index; CI,
confidence interval; RMSEA, root mean square error of approxima-
tion; SRMR, Standardized root mean square residual.
IDENTITY program
In the IDENTITY study program, the Spearman
rank correlation between ADAS-Cog14 and ADCS-
iADL was 0.392 at baseline and increased to 0.600
at 18 months (Fig. 2).
The model fit statistics were RMSEA = 0.07 with a
90% confidence interval of (0.06, 0.09), SRMR = 0.05,
and CFI = 0.98 for the IDENTITY study program
(Table 3). The cross-lagged regression coefficients
were significant for cognition predicting function for
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Table 4
ARCL panel analysis results for the 3 patient cohorts with mild AD dementia
Regression effect Cognition on function estimate (SE) Function on cognition estimate (SE)
EXPEDITION Placebo Baseline predicting 3 Month −0.06 (0.03)∗ −0.03 (0.03)
3 Month predicting 6 Month −0.09 (0.03)∗∗ 0.03 (0.03)
6 Month predicting 9 Month −0.04 (0.03) 0.06 (0.03)∗
9 Month predicting 12 Month −0.06 (0.03)∗ −0.04 (0.03)
12 Month predicting 15 Month −0.06 (0.03)∗ 0.05 (0.03)
15 Month predicting 18 Month −0.11 (0.02)∗∗∗ −0.01 (0.02)
IDENTITY Placebo Baseline predicting 3 Month −0.07 (0.04) 0.09 (0.06)
3 Month predicting 6 Month −0.09 (0.04)∗ −0.03 (0.05)
6 Month predicting 9 Month −0.09 (0.04)∗ 0.01 (0.4)
9 Month predicting 12 Month −0.13 (0.04)∗∗ 0.03 (0.04)
12 Month predicting 15 Month −0.07 (0.04) −0.02 (0.04)
15 Month predicting 18 Month −0.03 (0.04) 0.04 (0.04)
ADNI Baseline predicting 6 Month −0.01 (0.07) 0.05 (0.08)
6 Month predicting 12 Month 0.09 (0.05) 0.08 (0.07)
12 Month predicting 24 Month 0.19 (0.06)∗∗∗ −0.06 (0.06)
∗p< 0.05, ∗∗p< 0.01, ∗∗∗p< 0.001. EXPEDITION and IDENTITY include mild AD dementia patients treated with placebo. ADNI includes mild
AD dementia patients with no investigational treatment. All regression coefficients are standardized. Cognitive measures included: ADAS-Cog14
for EXPEDITION and IDENTITY study programs; ADAS-Cog11 for ADNI. Functional measures included: ADCS-iADL for EXPEDITION
and IDENTITY study programs; FAQ for ADNI. Note: significant coefficients are positive for only the ADNI dataset due to the difference in
directionality of the functional measures (higher ADCS-iADL and lower FAQ scores reflect more impairment). ADAS-Cog, AD Assessment
Scale-Cognitive subscales; ADCS-iADL, AD Cooperative Study-Activities of Daily Living instrumental subscale; ADNI, Alzheimer’s Disease
Neuroimaging Initiative; ARCL, autoregressive cross-lagged; FAQ, Functional Activities Questionnaire; SE, standard error.
3 of 6 time points (3 month predicting 6 month, 6
month predicting 9 month, and 9 month predicting
12 month), but not at any time points for function
predicting cognition (Table 4). Similar to the EXPE-
DITION study program results, in general, there was
a stronger cross-lagged coefficient for cognition pre-
dicting subsequent function than vice versa (Table 4).
Also analogous to the EXPEDITION results, the direc-
tion of the cross-lagged regression coefficient indicates
that a more impaired cognitive score predicts a more
impaired functional score at the subsequent visit.
ADNI
In the ADNI dataset, the Spearman rank correlation
between ADAS-Cog11 and FAQ was 0.414 at base-
line. By the end of the 24-month study, the correlation
increased to 0.561 (Fig. 2).
The model fit statistics for ADNI were RMSEA =
0.08 with a 90% confidence interval of (0.03, 0.12),
SRMR = 0.02 and CFI = 0.99 (Table 3). The cross-
lagged regression coefficients based on ADNI data
were significant for cognition predicting function at
one time point (12 month predicting 24 month),
but not at any of the time points for function pre-
dicting cognition (Table 4). The direction of the
cross-lagged coefficients was opposite from those for
the EXPEDITION and IDENTITY programs, because
higher scores on the FAQ indicate worsened func-
tion while lower scores indicate worsened function
for the ADCS-ADL. Therefore, the ADNI data, like
the EXPEDITION and IDENTITY data, indicates
that a more impaired cognitive score predicts a more
impaired functional score at the subsequent visit.
Similar results were observed in all three databases
when only completers were included in the cross-
lagged analyses.
DISCUSSION
This post-hoc analysis evaluated the temporal rela-
tionship between cognitive and functional impairment
during natural disease progression without investi-
gational treatment interventions in mild AD patients
using auto-regressive cross-lagged panel analyses.
Results from three independent datasets (EXPEDI-
TION, IDENTITY, and ADNI) demonstrated that
cognitive impairment preceded and predicted subse-
quent functional decline in mild AD dementia, but
functional impairment did not predict future cognitive
decline. These data are consistent with a causal effect
of cognition on function. In particular, the data showed
that a diminished cognitive ability is associated with
a worse functional outcome at the subsequent visit,
suggesting that cognitive decline will be followed by
future functional decline.
Previous studies have investigated the relationship
between clinical symptoms across the AD continuum
and the underlying pathology of the disease and have
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suggested that signs of dementia might not occur until
decades after the pathophysiological process begins
[4–10]. Biomarker studies suggest that amyloid pathol-
ogy may occur first followed by neurodegeneration
and cognitive symptoms [11, 32]. Additionally, recent
consensus statements postulate that targeting patients
with earlier forms of the illness provide the best chance
of slowing progression of the disease [10, 33–35].
Taken together, the findings from this post-hoc analy-
sis support the concept that in patients with mild AD
dementia, cognitive decline occurs early in the clinical
manifestation on the AD continuum and, if effective,
disease-modifying treatments may show effects on
cognition prior to consequential effects on function.
The results from this post-hoc analysis corroborate
the findings from a recent publication using similar
methodologies [24]. Zahodne and colleagues applied
ARCL panel analysis in two longitudinal studies, the
WHICAP and the Predictors Study, which included
non-demented older adults and mildly demented
AD patients, respectively. They found that cognitive
decline preceded and predicted subsequent functional
decline both prior to and after dementia onset. Others
have also reported that cognitive tests can predict
future impairment on activities of daily living before
onset of dementia [36–38] and some studies have
even suggested functional changes can predict con-
version from MCI to AD [39–41]. These studies have
shown substantial variability in rates of conversion,
consistent with the difficulty in identifying subtle func-
tional changes. To our knowledge, there have not been
other empirical data exploring the temporal relation-
ship between cognition and function in patients with
mild AD dementia.
Collectively, the conclusion that cognitive impair-
ment precedes and predicts functional impairment is
evidenced by replications across multiple independent
datasets. This includes three clinical trial cohorts of
mild AD dementia patients in this post-hoc analysis
and two cohorts (one population-based and one clini-
cal trial-based) in Zahodne et al. [24]. The validity is
further strengthened by consistent results across differ-
ent stages of the AD disease continuum as observed in
previous and current studies (2013) (both older adults
without dementia and mild AD patients). Additionally,
although the coefficients in the ADNI and EXPE-
DITION/IDENTITY study programs are in opposite
directions due to differences in scoring convention
(with the higher score of FAQ and lower score of
ADCS-ADL reflecting greater impairment), the mag-
nitude and interpretation of the results are similar.
These consistent findings are achieved despite the
fact that different instruments and scales for cognition
and function are used in the analyses, suggesting our
findings are independent to scale selection.
As pointed out by other authors [21], the ARCL
model is most useful in evaluating the temporal
ordering of two outcomes and in supporting potential
causal-effect directions in the relationships of the out-
comes. ARCL is utilized in this research to investigate
whether cognitive impairment precedes and predicts
subsequent functional impairment, or vice versa. It
is not the objective of this research to model pre-
cise quantitative measures of the trajectory of disease
progression in AD dementia, which is a complex
undertaking. Future research is needed to compre-
hensively characterize this quantitative relationship
between cognition and function using more sensitive
measures and additional representative models of dis-
ease progression.
While the ARCL panel analyses demonstrated that
cognitive impairment predicts functional impairment
in the natural course of the disease, an additional
statistical approach has been used to investigate the
influence of cognitive treatment effect on functional
treatment effect. In a previous study, path analysis was
used to assess the relationship between the treatment
effect of solanezumab on the slowing of cognitive and
functional decline using pooled data from patients with
mild AD who participated in the EXPEDITION and
EXPEDITION2 studies [25]. In that study, path anal-
yses determined that the treatment effect on function
was primarily driven by the direct treatment effect on
cognition. Combined with the ARCL panel analyses,
these findings support the idea that slowing cognitive
impairment can be considered an intermediate step to
slowing functional impairment in mild AD dementia.
There are limitations of these post-hoc analyses.
Although the results were consistent across various
clinical measures commonly used in AD clinical tri-
als, the findings are based on existing cognitive and
functional scales. More sensitive clinical diagnostic
tools might reveal subtle changes in earlier disease
stages, including mild AD dementia. For example,
while ADAS-Cog and ADCS-iADL showed a good
correlation based on current data, a cognitive scale that
is more sensitive to executive function may establish
an even stronger relationship and greater magnitude of
association with activities of daily living [42, 43]. An
optimized functional measure designed to assess very
mild functional change and with culturally neutral ele-
ments, might be more applicable to a mildly affected
patient population such as the ones studied here and
may allow detection of greater magnitude of impact of
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cognitive impairment on functional impairment. Addi-
tionally, the power of the models may have been limited
due to a smaller sample size of the ADNI dataset
and the early termination of the IDENTITY program,
leading to the reduced availability of data, especially
toward the later time points of the study. Lastly, the
analysis is limited to patients with mild AD dementia
and there may be different cognitive-functional rela-
tionships in later, more severe disease states.
The early stages of symptomatic AD are primarily
defined by cognitive impairment that may have clin-
ical implications for patients even before functional
impairment is measurable (e.g., patients with prodro-
mal AD or MCI). Our analyses support the causal
effect of cognitive impairment on subsequent func-
tional impairment for patients with mild AD dementia.
Disease-modifying treatments designed to disrupt
underlying AD pathophysiology early in the disease
process might be expected to slow the progression of
cognitive symptoms, while effects on function may
take longer to observe. If cognitive impairment pre-
cedes and predicts functional impairment in the natural
course of AD, cognition may be used as an indicator of
future functional outcomes and should be considered
a critical target for prevention strategies to limit future
functional decline. Taken together, understanding the
temporal relationship between cognition and function
has real world implications and may lead to more effec-
tive and efficient strategies for drug development in
early AD. Further, it may enable appropriate expec-
tations for outcomes with putative disease-modifying
therapies studied in earlier stages of AD.
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